Biogen CEO Vounatsos laments 'confusion' and 'misinformation' leading to challenges with Aduhelm uptake
Biogen CEO Michel Vounatsos on Thursday admitted the company is experiencing some “near term challenges” in launching its controversial new Alzheimer’s drug, a little more than two months since winning an accelerated approval.
“There is clearly too much confusion, misinformation and controversy surrounding our data and the approval process,” Vounatsos said at a JP Morgan health care conference. Indeed, the HHS Inspector General has opened an investigation into the approval, in addition to an internal FDA investigation, which was revealed by a Congressional investigation into the approval and the close ties between FDA and Biogen.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 118,600+ biopharma pros reading Endpoints daily — and it's free.